9/28/2023 0 Comments Bpmc stock forecast![]() ![]() ![]() You agree that you understand that Pluto is not an investment adviser or a broker-dealer and does not have a fiduciary duty to you or a duty to act in your best interests. Pluto also does not provide you with legal, tax, or accounting advice. If you want to receive individualized investment advice, you should consult with your own financial adviser. Pluto is a technology provider that provides you with information, software, and automation tools for the purpose of investment education, but it does not make investment recommendations of securities, investment strategies, or account types, either in general or individualized for you or any other subscriber. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. and changed its name to Blueprint Medicines Corporation in June 2011. The company was formerly known as Hoyle Pharmaceuticals, Inc. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Proteovant Therapeutics CStone Pharmaceuticals Genentech, Inc. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive BLU- 222 to treat patients with cyclin E aberrant cancers and BLU-852 for the treatment of advanced cancers. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC) and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. ![]() The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |